Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lantheus stock | $14.78

Own Lantheus stock in just a few minutes.

Fact checked

Lantheus Holdings, Inc is a diagnostics & research business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Lantheus employs 508 staff and has a trailing 12-month revenue of around USD$334.6 million.

How to buy shares in Lantheus

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Lantheus. Find the stock by name or ticker symbol: LNTH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Lantheus reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$14.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Lantheus, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Lantheus. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Lantheus share price

Use our graph to track the performance of LNTH stocks over time.

Lantheus shares at a glance

Information last updated 2020-12-10.
Latest market closeUSD$14.78
52-week rangeUSD$8.67 - USD$21.42
50-day moving average USD$12.4293
200-day moving average USD$13.4026
Wall St. target priceUSD$19.25
PE ratio 1861.25
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.008

Buy Lantheus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lantheus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lantheus price performance over time

Historical closes compared with the close of $14.78 from 2020-12-09

1 week (2021-01-13) -5.86%
1 month (2020-12-23) -0.34%
3 months (2020-10-20) 13.96%
6 months (2020-07-20) -5.50%
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) 22.8
5 years (2016-01-20) 508.23%

Is Lantheus under- or over-valued?

Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lantheus's P/E ratio

Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1861x. In other words, Lantheus shares trade at around 1861x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Lantheus's PEG ratio

Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Lantheus's EBITDA

Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$46.3 million.

The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.

Lantheus financials

Revenue TTM USD$334.6 million
Operating margin TTM 7.93%
Gross profit TTM USD$174.8 million
Return on assets TTM 2.59%
Return on equity TTM 0.13%
Profit margin 0.12%
Book value $7.683
Market capitalisation USD$995.7 million

TTM: trailing 12 months

Shorting Lantheus shares

There are currently 2.0 million Lantheus shares held short by investors – that's known as Lantheus's "short interest". This figure is 8.4% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting Lantheus shares can be evaluated.

Lantheus's "short interest ratio" (SIR)

Lantheus's "short interest ratio" (SIR) is the quantity of Lantheus shares currently shorted divided by the average quantity of Lantheus shares traded daily (recently around 461655.60640732). Lantheus's SIR currently stands at 4.37. In other words for every 100,000 Lantheus shares traded daily on the market, roughly 4370 shares are currently held short.

However Lantheus's short interest can also be evaluated against the total number of Lantheus shares, or, against the total number of tradable Lantheus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lantheus's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Lantheus shares in existence, roughly 30 shares are currently held short) or 0.0381% of the tradable shares (for every 100,000 tradable Lantheus shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lantheus.

Find out more about how you can short Lantheus stock.

Lantheus share dividends

We're not expecting Lantheus to pay a dividend over the next 12 months.

Lantheus share price volatility

Over the last 12 months, Lantheus's shares have ranged in value from as little as $8.67 up to $21.42. A popular way to gauge a stock's volatility is its "beta".

LNTH.US volatility(beta: 1.33)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 1.3312. This would suggest that Lantheus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lantheus overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; and strategic collaboration with Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site